US20040127446A1
(en)
*
|
1992-05-14 |
2004-07-01 |
Lawrence Blatt |
Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
|
US5807718A
(en)
*
|
1994-12-02 |
1998-09-15 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
US7141665B1
(en)
*
|
1998-04-29 |
2006-11-28 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
US5910408A
(en)
*
|
1995-06-07 |
1999-06-08 |
The General Hospital Corporation |
Catalytic DNA having ligase activity
|
US20040102389A1
(en)
*
|
1995-10-26 |
2004-05-27 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
US20040220128A1
(en)
*
|
1995-10-26 |
2004-11-04 |
Sirna Therapeutics, Inc. |
Nucleic acid based modulation of female reproductive diseases and conditions
|
US7034009B2
(en)
|
1995-10-26 |
2006-04-25 |
Sirna Therapeutics, Inc. |
Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
ATE213019T1
(en)
*
|
1995-11-14 |
2002-02-15 |
Vimrx Holdings Ltd |
CHIMERIC OLIGOMERS HAVING RNA-CLEGATING ACTIVITY
|
CA2275964A1
(en)
*
|
1996-12-24 |
1998-07-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis of nucleosides and polynucleotides
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
CA2287520C
(en)
*
|
1997-04-29 |
2010-12-14 |
The Scripps Research Institute |
Enzymatic dna molecules
|
JP2003525017A
(en)
*
|
1998-04-20 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Nucleic acid molecules with novel chemical composition that can regulate gene expression
|
WO2002081628A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
AU3986201A
(en)
*
|
2000-02-24 |
2001-09-03 |
Glaxo Group Limited |
Method and reagent for the inhibition of grid
|
US20040009510A1
(en)
*
|
2000-03-06 |
2004-01-15 |
Scott Seiwert |
Allosteric nucleic acid sensor molecules
|
US20020102694A1
(en)
*
|
2000-03-31 |
2002-08-01 |
Ronald Breaker |
Nucleozymes with endonuclease activity
|
EP1702983A3
(en)
|
2000-04-13 |
2007-01-10 |
Medical University of South Carolina |
Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
|
US20080242627A1
(en)
*
|
2000-08-02 |
2008-10-02 |
University Of Southern California |
Novel rna interference methods using dna-rna duplex constructs
|
WO2002011674A2
(en)
*
|
2000-08-09 |
2002-02-14 |
Ribozyme Pharmaceuticals, Incorporated |
Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
JP2004527220A
(en)
*
|
2000-09-13 |
2004-09-09 |
アルケミックス コーポレイション |
Target activated nucleic acid biosensor and method of using same
|
US7125660B2
(en)
*
|
2000-09-13 |
2006-10-24 |
Archemix Corp. |
Nucleic acid sensor molecules and methods of using same
|
AU2001296846B2
(en)
|
2000-10-12 |
2007-07-05 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
CA2442092A1
(en)
*
|
2001-03-26 |
2002-10-17 |
Ribozyme Pharmaceuticals, Inc. |
Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
|
US20040063922A1
(en)
*
|
2001-04-17 |
2004-04-01 |
Conrad Charles A. |
Methods and compositions for catalytic DNA exchange in a sequence specific manner
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
EP1572067A4
(en)
|
2001-05-18 |
2009-05-13 |
Sirna Therapeutics Inc |
Conjugates and compositions for cellular delivery
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
EP1390472A4
(en)
*
|
2001-05-29 |
2004-11-17 |
Sirna Therapeutics Inc |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
US20030140362A1
(en)
*
|
2001-06-08 |
2003-07-24 |
Dennis Macejak |
In vivo models for screening inhibitors of hepatitis B virus
|
US7811992B2
(en)
|
2002-02-06 |
2010-10-12 |
Stasys Technologies, Inc. |
Anti-infarction molecules
|
US7071311B2
(en)
*
|
2002-02-13 |
2006-07-04 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for 2′-C-allyl nucleic acids
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
WO2003093452A2
(en)
*
|
2002-02-26 |
2003-11-13 |
University Of Utah Research Foundation |
Variants of nedd4l associated with hypertension and viral budding
|
US20030224435A1
(en)
*
|
2002-05-16 |
2003-12-04 |
Scott Seiwert |
Detection of abused substances and their metabolites using nucleic acid sensor molecules
|
US20040002106A1
(en)
*
|
2002-05-16 |
2004-01-01 |
Dipankar Sen |
RNA cleaving DNA enzymes and methods of making and using same
|
CA2495478A1
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
EP2322535A3
(en)
*
|
2002-09-20 |
2011-09-28 |
Yale University |
Riboswitches, methods for their use, and compositions for use with riboswitches
|
US9233120B2
(en)
|
2002-11-15 |
2016-01-12 |
Jyant Technologies |
Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
|
US8658377B2
(en)
|
2002-11-15 |
2014-02-25 |
Morehouse School Of Medicine |
Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
|
US8512701B2
(en)
|
2002-11-15 |
2013-08-20 |
Morehouse School Of Medicine |
Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
|
EP1622572B1
(en)
|
2003-04-30 |
2017-12-20 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US9453219B2
(en)
*
|
2003-05-15 |
2016-09-27 |
Mello Biotech Taiwan Co., Ltd. |
Cosmetic designs and products using intronic RNA
|
US20050042212A1
(en)
*
|
2003-07-24 |
2005-02-24 |
Nanda Steven A. |
Method of reducing CRF receptor mRNA
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
CA2595440A1
(en)
|
2005-02-02 |
2006-08-10 |
The Uab Research Foundation |
Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
|
SG10201912554TA
(en)
|
2005-03-23 |
2020-02-27 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
CA2625349A1
(en)
*
|
2005-10-06 |
2007-04-19 |
Emthrax, Llc |
Methods and compositions relating to anthrax spore glycoproteins as vaccines
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1934331A4
(en)
|
2005-10-14 |
2009-01-21 |
Musc Found For Res Dev |
Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
|
US8313901B2
(en)
*
|
2005-12-21 |
2012-11-20 |
Yale University |
Methods and compositions related to the modulation of riboswitches
|
EP2061799A4
(en)
*
|
2006-09-11 |
2010-12-22 |
Univ Yale |
Methods and compositions for the use of lysine riboswitches
|
CA2664189C
(en)
|
2006-09-21 |
2017-11-21 |
University Of Rochester |
Compositions and methods related to protein displacement therapy for myotonic dystrophy
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
EP2104509A4
(en)
*
|
2006-12-11 |
2010-03-24 |
Univ Utah Res Found |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
AU2008266684A1
(en)
*
|
2007-05-29 |
2008-12-24 |
Yale University |
Riboswitches and methods and compositions for use of and with riboswitches
|
CN101688251A
(en)
*
|
2007-05-29 |
2010-03-31 |
耶鲁大学 |
Methods and compositions related to riboswitches that control alternative splicing and rna processing
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
DK2682400T5
(en)
*
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Synthetic apolipoprotein E mimic polypeptides and methods of use
|
EP2268664B1
(en)
*
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
US20090233993A1
(en)
*
|
2008-03-06 |
2009-09-17 |
Burnham Institute For Medical Research |
Compositions and methods for inhibiting gsk3 activity and uses thereof
|
EP2288922B1
(en)
|
2008-05-08 |
2016-08-17 |
University of Utah Research Foundation |
Sensory receptors for chronic fatigue and pain and uses thereof
|
EP2370080A1
(en)
|
2008-12-02 |
2011-10-05 |
University of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
US20110060000A1
(en)
|
2009-09-10 |
2011-03-10 |
Maurizio Grimaldi |
Acridine analogs in the treatment of gliomas
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
EP3372684B1
(en)
|
2010-08-24 |
2020-10-07 |
Sirna Therapeutics, Inc. |
Single-stranded rnai agents containing an internal, non-nucleic acid spacer
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2016018665A1
(en)
|
2014-07-31 |
2016-02-04 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
US10723794B2
(en)
|
2015-03-18 |
2020-07-28 |
University Of South Carolina |
Anti-CcL8 antibodies and uses thereof
|
US11123435B2
(en)
|
2016-08-03 |
2021-09-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
TLR9 targeted therapeutics
|
WO2021182474A1
(en)
*
|
2020-03-12 |
2021-09-16 |
株式会社Frest |
Oligonucleotide and target rna site-specific editing method
|